RMP
HRMY icon

Richards, Merrill & Peterson’s Harmony Biosciences HRMY Stock Holding History

Richards, Merrill & Peterson’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$241 – 509
2024
Q4 		$241 Buy
+7
New +$241 ﹤0.01% 485

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Richards, Merrill & Peterson's HRMY Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Harmony Biosciences (HRMY) in Q1 2025, closing a stake of 7 shares — an estimated $241 sold.

Richards, Merrill & Peterson first reported a position in HRMY in Q4 2024 and held it in 1 quarter. The position peaked at $241 in Q4 2024. 272 funds tracked by Wall St. Rank hold HRMY as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Harmony Biosciences position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 7 Harmony Biosciences shares in Q1 2025, an estimated $241.
  • Richards, Merrill & Peterson first reported a position in Harmony Biosciences in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Harmony Biosciences position peaked at $241 in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.